Objective-Patients with peripheral artery disease are at risk for critical limb ischemia and amputation. Accumulation of advanced glycation end products is increased and predictive for coronary and cerebrovascular events in several high cardiovascular risk groups. We hypothesized that accumulation of tissue advanced glycation end products, measured by skin autofluorescence (SAF), predicts amputation in patients with peripheral artery disease.
A mputation is a severe outcome for patients with peripheral artery disease (PAD). A recent study in almost 3 million inpatients hospitalized for PAD demonstrated that 5.8% underwent an amputation during the study period of 8 years. 1 Several risk scores are designed to predict the risk of lower limb amputation. Finnvasc and PREVENT III risk scores use cardiovascular risk factors and clinical condition to predict amputation, including diabetes mellitus, coronary artery disease, and tissue loss. 2 Disadvantages of these risk scores are that these models are only designed to predict outcome after a revascularization procedure. Furthermore, PREVENT III and Finnvasc risk scores are only validated in patients with Fontaine stage III and IV, who have an obvious increased risk for amputation. Also the area under the curves (AUCs) for these prediction models are below 0.70, and therefore should be used with caution. Fontaine classification itself was developed to classify clinical stages of PAD and not as a predictor of amputation. No simple model that can predict amputation at all Fontaine stages and in particular at lower Fontaine stages is available.
Advanced glycation end products (AGEs) are metabolic or oxidative stress-derived end products of sugars, usually proteinbound. 3 Ageing causes accumulation of AGEs, mainly because of oxidative stress. Elevated AGEs levels are found in patients with increased glycemic or oxidative stress, such as diabetes mellitus and renal insufficiency. 4, 5 Oxidative stress markers are increased in PAD. 6, 7 Skin autofluorescence (SAF) is a validated noninvasive method to assess accumulation of tissue AGEs in the skin. 8 Earlier, we showed that SAF is increased in patients with PAD, irrespective of diabetes mellitus and renal insufficiency and is also a predictor for cardiovascular morbidity and all-cause mortality in patients with PAD. 9,10 However, the
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
In short, we performed a single-center prospective cohort study of 252 patients with established PAD. Deposition of tissue AGEs was noninvasively measured by skin autofluorescence with the AGE Reader. Five-year follow-up data were analyzed. The end point was defined as amputation caused by critical limb ischemia. Amputationfree survival was analyzed by Kaplan-Meier plot with log-rank test, according to the optimal cutoff value of SAF (generated by the receiver operating characteristics curve) and to subdivision into 4 groups, based on Fontaine stage (I-II versus III-IV) and SAF below or above the cutoff value. Subproportional hazard ratios (sHR) for amputation risk with 95% confidence interval (CI) were calculated by competing risks regression analysis, with death as the competing risk. Additional log-rank and competing risks regression analyses were performed in patients with Fontaine stage I and II. Receiver operating characteristics analysis was performed, with Fontaine stage and Fontaine stage multiplied by SAF. The study was approved by the local institutional review board, and all participating patients gave informed consent.
Results

Patients Characteristics and SAF
A total of 267 patients were willing to participate. Fifteen patients were excluded because of hemodialysis (n=4), kidney transplantation (n=8), a recent myocardial infarction (n=1), and a recent stroke (n=2). Baseline characteristics of the 252 patients with PAD (mean age, 66±11 years) are shown in Table 1 . In 38 (15%) patients, ankle-brachial index was not measured because PAD had already been established by imaging of the lower arteries (n=12) or a revascularization procedure (n=26) was performed directly. Sixty-six (26%) patients were classified as Fontaine stage I, 149 (59%) as Fontaine stage II, 21 (8%) as Fontaine stage III, and 16 (7%) patients as Fontaine stage IV. Mean anklebrachial index was 0.57±0.15. At baseline, 152 (60%) patients had an intervention for their PAD, including 21 (8%) amputations because of critical limb ischemia. Of the patients with current Fontaine stage I or II, 127 (59%) patients had a history of intervention whereas 88 (41%) had not. Of the patients with current Fontaine stage III and IV, 25 (68%) had a history intervention whereas 12 (32%) had not. Seventy-four (29%) patients had diabetes mellitus. Mean SAF was 2.76±0.66 arbitary units.
Five-Year Follow-Up
Median follow-up duration was 5.3 (interquartile range, 4.7-5.7) years. Of the 252 patients who were included, 72 (29%) patients died, 3 (1%) patients withdrew consent, and 2 (1%) patients were lost to follow-up. During follow-up, 46 (18%) patients underwent percutaneous transluminal angioplasty, 34 (13%) bypass surgery, 13 (5%) endarterectomy, and 3 (1%) thrombolysis for their PAD. Amputation occurred in 23 (9%) of the patients. One noncritical limb ischemia induced amputation was performed in a patient who had claw toes, which was not included into the analyses. Therefore, a total of 22 (9%) amputations were analyzed. The number of major (above ankle) and minor (below ankle) amputations was 5 (2%) and 17 (7%), respectively. Other interventions for PAD were performed: 46 (18%) percutaneous transluminal angioplasty, 34 (13%) bypass surgery, 13 (5%) endarterectomy, and 3 (1%) thrombolysis. The Kaplan-Meier analysis ( Figure 1) shows an cumulative amputation-free survival of 96% in patients below the cutoff value (SAF, 2.90 arbitrary units) of SAF and 70% in the patient group above the cutoff value of SAF (log-rank, P<0.0001). The univariate and multivariate competing risks regression analyses are shown in Table 2 . In the univariate model, a higher SAF was associated with increased risk of amputation, sHR per unit increase: 3.05 (95% CI, 1.87-4.96); P<0.0001. The variables SAF, diabetes mellitus, and Fontaine stage were entered into the multivariate model. Per unit increase of SAF, the sHR for amputation was 2.72 (95% CI, 1.38-5.39); P=0.004. In a sensitivity analysis, we repeated the Kaplan-Meier and competing risks regression analyses for patients with and without diabetes mellitus. For both patients with and without diabetes mellitus, SAF>2.90 was associated with a higher risk of amputation when compared with SAF<2.90; log-rank P=0.002 and P=0.003, respectively. Also with competing risks regression analyses, SAF was associated with amputation in a univariate and multivariate model in the patients without diabetes mellitus: sHR, 3.09 (1.44-6.62; P=0.004) and sHR, 3.41 (1.50-7.81; P=0.004), respectively. In the diabetic patients, SAF remained associated with amputation in the univariate model; 2.80 (1.24-6.31); P=0.01. However, SAF was no longer significantly associated with amputation in a multivariate model that included Fontaine classification in these patients. This is probably explained by the low number of patients with diabetes mellitus (n=74) when compared with larger number of patients without diabetes mellitus (n=178). Figure 2 shows the Kaplan-Meier analysis with 4 groups based on Fontaine stage (I and II versus III and IV) and SAF (below and above cutoff value), log-rank P<0.0001. In addition, analyses of patients at lower Fontaine stage (I or II) only were performed. In these patients, Kaplan-Meier analysis showed a significant difference of amputation-free survival between patients below (group 1) and above (group 2) the cutoff value of SAF; log-rank P=0.0001. Univariate competing risks regression analysis of patients at lower Fontaine stage showed a sHR per unit increase of SAF of 4.05 (95% CI, 2.09-7.83); P<0.0001 for amputation. Additional multivariate competing risks analysis was not performed, because age, sex, smoking status, presence of diabetes mellitus, estimated glomerular filtrating rate, history of coronary artery or cerebrovascular disease, hypertension, the use of lipid-lowering drugs, and Fontaine stage did not achieve a P<0.10 in a univariate model. A subgroup analysis was performed for the predictive value of SAF for minor (below ankle) amputations only. The results of the Kaplan-Meier analysis, 
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Receiver Operating Characteristics Curve
The AUC (Figure 3) for Fontaine stage as only predictor of amputation was 0.74 (95% CI, 0.63-0.86). The AUC for SAF was 0.76 (95% CI, 0.66-0.85). Fontaine stage multiplied by SAF resulted in a significant increase of the AUC to 0.83 (95% CI, 0.74-0.92) when compared with Fontaine classification, P=0.003. AUC of SAF was not significantly different from the AUC of the multiplication of Fontaine stage by SAF, P=0.24.
Discussion
This study shows that SAF, as a measure of tissue AGE accumulation, predicts amputation in patients with PAD, independent of diabetes mellitus and Fontaine stage. Moreover, in patients at lower Fontaine stage (I and II), SAF is the only marker that predicts amputation. In the total cohort, multiplication of Fontaine stage by SAF results in a good prediction model for amputation.
AGEs in PAD
Increased AGE levels in PAD were earlier reported in several studies. The first study which showed an association between PAD and AGEs was a small cross-sectional study in diabetic patients with and without PAD versus healthy controls. 11 This study showed highest serum levels of AGEs and pentosidine in diabetic patients with PAD, followed by diabetic patients without PAD and lowest values in healthy controls. In a study of patients with carotid artery disease, we found that increased SAF was confined to the patients with concomitant PAD. 12 In an earlier study of 492 patients with PAD, we reported increased levels of SAF, also after correction for cardiovascular risk factors and comorbidity, including diabetes mellitus and renal function. 9 The predictive value of SAF for all-cause or cardiovascular mortality and cardiovascular events was previously shown in patients with PAD, diabetes mellitus, renal insufficiency, and myocardial infarction and for disease progression in chronic kidney disease. 10, [13] [14] [15] [16] This study is the first to show that SAF is an independent predictor for leg outcome in patients with PAD. These results underscore the role of AGEs as predictor for progression of atherosclerosis beyond diabetes mellitus and renal insufficiency.
SAF and Clinical Decision Making
Decision making for intervention for PAD is primarily based on clinical presentation as judged by the vascular surgeons and Fontaine stage. In Fontaine stage III and IV, a severe natural fate is common, with a reported 1-year amputation rate in patients with critical limb ischemia of 25% and 25% 1-year cardiovascular mortality. 17 Indeed, also in our data most of the amputations in Fontaine stage III and IV occurred during the first year. Therefore, the additional clinical value of SAF as prediction tool is particularly valid for patients with mild and moderate symptoms. Combining SAF and current Fontaine stage leads to the highest AUC. Of note, all of the patients in the subgroup Fontaine I or II that had an amputation during follow-up already had a history of intervention for PAD. Extended follow-up of the patients without a history of intervention could answer the question whether SAF is useful to identify high-risk patients with newly diagnosed PAD.
Study Strengths and Limitations
The main strengths of this study are the low number of patients lost to follow-up (n=2; 1%) and the duration of the followup (5.3 years). In addition, careful patient selection was performed. Patients with conditions that interfere with SAF measurements were excluded from participation (recent myocardial infarction, stroke, or sepsis, renal replacement therapy, active cancer, and solid organ transplantation) or were corrected (diabetes mellitus) in the analyses. A limitation of our study is that we only assessed the relation of SAF with traditional risk factors, but not with specific markers for inflammation, oxidative stress, or endothelial dysfunction. Furthermore, it is unknown whether SAF, as a measurement of skin AGEs, reflects the amount of AGEs in the arterial wall. Only one study described a strong correlation between SAF and a collagenase digestible collagen fraction, as a measure of AGEs content, in vein tissue of patients undergoing a coronary artery bypass graft with vein graft material. 18 And last, the use of the AGE Reader is only possible in patients with skin types up to Fitzpatrick type V. In darkskinned patients, light is absorbed excessively, not allowing a reliable measurement of SAF.
Conclusion
SAF, as a measure of AGEs, predicts amputation in patients with PAD after a 5-year follow-up, independent from presence of diabetes mellitus and Fontaine stage. Even in patients at lower Fontaine stage (I or II), SAF is a strong predictor of amputation and provides additional value in clinical decision making. A simple model of a combination of SAF and Fontaine stage shows a good prediction of amputation. 
Disclosures
